ETF Holdings Breakdown of ELVN

News associated with ELVN

Exchange Traded Concepts LLC Reduces Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Exchange Traded Concepts LLC decreased its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 19.1% in the 1st quarter, Holdings Channel.com reports. The firm owned 6,055 shares of the company’s stock after selling 1,428 shares during the period. Exchange Traded Concepts LLC’s holdings in Enliven Therapeutics were worth $119,000 as of its most […] - 2025-06-24 07:38:52

Rhumbline Advisers Increases Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Rhumbline Advisers raised its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 4.9% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 52,502 shares of the company’s stock after acquiring an additional 2,466 shares during the period. Rhumbline Advisers’ holdings in Enliven Therapeutics were worth $1,033,000 […] - 2025-06-20 07:22:47

Robert W. Baird Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) had its target price lifted by equities research analysts at Robert W. Baird from $40.00 to $52.00 in a report issued on Monday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird’s price target indicates a potential upside of 138.53% from the stock’s […] - 2025-06-18 06:08:46

Enliven Therapeutics (NASDAQ:ELVN) Coverage Initiated at The Goldman Sachs Group

Investment analysts at The Goldman Sachs Group assumed coverage on shares of Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) in a report released on Monday, MarketBeat Ratings reports. The firm set a “buy” rating and a $37.00 price target on the stock. The Goldman Sachs Group’s target price suggests a potential upside of 69.72% from […] - 2025-06-18 06:08:45

Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up Following Analyst Upgrade

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report)’s stock price gapped up prior to trading on Monday after Robert W. Baird raised their price target on the stock from $40.00 to $52.00. The stock had previously closed at $21.91, but opened at $23.38. Robert W. Baird currently has an outperform rating on the stock. Enliven […] - 2025-06-17 05:08:49

Two Sigma Investments LP Decreases Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Two Sigma Investments LP lowered its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 33.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 14,620 shares of the company’s stock after selling 7,460 shares during the quarter. Two Sigma Investments LP’s holdings in Enliven Therapeutics were worth $329,000 as of its […] - 2025-06-11 07:30:51

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 3.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,036 shares of the company’s stock after purchasing an additional 718 shares during the […] - 2025-05-30 07:55:02

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Recommendation of “Buy” by Brokerages

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) have been assigned an average rating of “Buy” from the five analysts that are covering the company, MarketBeat reports. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month […] - 2025-05-27 08:26:58

Voya Investment Management LLC Decreases Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Voya Investment Management LLC trimmed its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 8.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,702 shares of the company’s stock after selling 945 shares during the quarter. Voya […] - 2025-05-13 08:22:51

Marshall Wace LLP Has $931,000 Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Marshall Wace LLP cut its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 70.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 41,382 shares of the company’s stock after selling 96,624 shares during the quarter. Marshall Wace LLP’s holdings in Enliven Therapeutics were worth $931,000 at the end […] - 2025-05-01 07:50:53

ExodusPoint Capital Management LP Acquires New Shares in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

ExodusPoint Capital Management LP bought a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 8,900 shares of the company’s stock, valued at approximately $200,000. Other hedge funds have also added to or reduced […] - 2025-04-15 07:39:25

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by Fmr LLC

Fmr LLC grew its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 3.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,495,871 shares of the company’s stock after acquiring an additional 199,692 shares during the quarter. Fmr LLC owned about 0.13% […] - 2025-04-14 08:48:47

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock Holdings Lowered by Corebridge Financial Inc.

Corebridge Financial Inc. cut its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 7.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,500 shares of the company’s stock after selling 1,321 shares during the quarter. […] - 2025-04-10 07:49:04

Enliven Therapeutics (NASDAQ:ELVN) Shares Down 4.9% Following Insider Selling

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report)’s share price traded down 4.9% during mid-day trading on Tuesday following insider selling activity. The stock traded as low as $18.61 and last traded at $18.73. 40,658 shares were traded during mid-day trading, a decline of 85% from the average session volume of 275,231 shares. The stock […] - 2025-04-03 05:44:44

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst Says

Enliven Therapeutics (NASDAQ:ELVN – Free Report) had its price objective lifted by HC Wainwright from $37.00 to $39.00 in a research report sent to investors on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. Separately, BTIG Research began coverage on Enliven Therapeutics in a report on Friday, December 13th. They set […] - 2025-03-24 06:13:03

ELVN institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-06-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	46,916	USD 1,009,632
2025-06-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	24,616	USD 529,736
2025-06-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	24,616	USD 529,736
2025-06-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	1,946	USD 41,878
Total =		98,094	USD 2,110,982

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer